版本:
中国

BRIEF-OPKO provides update to late-stage study of HGH-CTP in growth hormone deficient adults

June 15 OPKO Health Inc-

* OPKO provides update to topline data of phase 3 clinical study of hgh-ctp in growth hormone deficient adults

* OPKO Health - completed post-hoc sensitivity analyses to evaluate influence of outliers on primary endpoint results using multiple statistical approaches

* OPKO Health Inc - additional analyses that did not exclude outliers showed mixed results

* OPKO Health - analyses that excluded outliers showed a statistically significant difference between hgh-ctp and placebo on change in trunk fat mass

* OPKO Health Inc - preparation for pivotal pediatric ghd trial in japan is progressing and site selection is near completion

* OPKO Health - plans to utilize multi-dose pen for patients who continue in open label extension phase of adult phase 3, pediatric phase 2 ghd studies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐